About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06371573

Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Adult patients (\>18 years) with newly diagnosis of Ph negative myeloproliferative neoplasms (MPNs) according to WHO 2016 criteria, will be recruited to this study. This study is the result of the co...

Lead sponsor: Federico II University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Federico II University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•diagnosis of Philadelphia (Ph) negative chronic myeloproliferative neoplasms (MPN), according to WHO 2016 criteria
•age \>18 years
•execution of MRI of the upper abdomen within two weeks from the US,

Related studies

RECRUITINGPhase 1

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587 · Acute Myeloid Leukemia, Leukemia, and more

RECRUITINGPhase 1

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805 · Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, and more

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more

RECRUITINGPhase 1/2

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT04140487 · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, and more

RECRUITINGPhase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 17, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment45

Start dateApr 2017

Last updatedApr 17, 2024

Condition

Myeloproliferative Neoplasm Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis Prefibrotic/Early Primary Myelofibrosis

Locations shown

Federico II University

Naples

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2024Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions